Why Beta Bionics, Inc.’s (BBNX) Stock Is Down 5.70%
As of Tuesday, September 29, Beta Bionics, Inc.’s BBNX share price has dipped by 5.70%, which has investors questioning if this is right time to buy.Jenna Brashear
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Beta Bionics, Inc., a commercial-stage medical device company, engages in the design, development, and commercialization of solutions to enhance the health and quality of life of insulin-requiring people with diabetes. It offers iLet Bionic Pancreas, an insulin delivery device for the treatment of type 1 diabetes in adults and children six years of age and older. The company is also developing Patch Pump, an insulin pump that is designed to adhere directly to the skin and administer insulin without the need for tubing; Bihormonal iLet, which combines automated delivery of insulin and glucagon; and iLet to treat people with insulin-dependent type-2 diabetes. It has collaboration and license agreement with Xeris Pharmaceuticals, Inc. (Xeris) to develop and commercialize a pump-compatible glucagon formulation; and development and commercialization agreement with Abbott Diabetes Care Inc. to develop and commercialize an automated insulin delivery system. The company was incorporated in 2015 and is headquartered in Irvine, California.
Commentary & Analysis
Why Beta Bionics, Inc.’s (BBNX) Stock Is Up 6.58%
As of Tuesday, September 22, Beta Bionics, Inc.’s BBNX share price has surged by 6.58%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
Why Beta Bionics, Inc.’s (BBNX) Stock Is Down 5.37%
As of Thursday, September 17, Beta Bionics, Inc.’s BBNX share price has dipped by 5.37%, which has investors questioning if this is right time to buy.Rosalio Madrigal
Why Beta Bionics, Inc.’s (BBNX) Stock Is Up 8.42%
As of Wednesday, September 16, Beta Bionics, Inc.’s BBNX share price has surged by 8.42%, which has investors questioning if this is right time to sell.Michael Rose
Why Beta Bionics, Inc.’s (BBNX) Stock Is Up 5.62%
As of Tuesday, September 15, Beta Bionics, Inc.’s BBNX share price has surged by 5.62%, which has investors questioning if this is right time to sell.Jenna Brashear
Financial Summary
| Share Statistics | BBNX | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $993.4 | $378.7 | 46% |
|
| Shares Out (Mil) | 44.5 | 41.2 | 45% |
|
| Institutional Ownership | 94.5% | 82.9% | 65% |
|
| Float (Mil) | 36.5 | 35.5 | 40% |
|
| Beta | na | 0.86 | na |
|
| Avg Daily Volume (000s) | 1,174 | 351 | 71% |
|
| Price Change (52-week) |
(5.0%) | 64.6% | 48% |
|
| Growth | BBNX | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 11.8% | na |
|
| Net Income (5yr) | na | (5.7%) | na |
|
| EPS (5yr) | na | 10.2% | na |
|
| Dividends (5yr) | na | 0.0% | 0% |
|
| Cash Flow (5yr) | na | (15.5%) | na |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 2 | 2 | 2 | |
| Current EPS | ($0.495) | ($1.835) | ($2.325) | |
| Month Ago EPS | ($0.510) | ($1.895) | ($2.315) | |
| # Rev Up | 2 | 3 | 3 | |
| # Rev Down | 0 | 2 | 2 | |
| Three Months Ago EPS | ($0.527) | ($2.107) | ($2.390) | |
| Year/Year Chg | (5.7%) | 1.6% | 22.1% | |
| Financials | BBNX | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $119 | $128 | 28% |
|
| Net Income (TTM) (Mil) | ($73) | ($9) | 14% |
|
| EPS (TTM) | ($1.649) | ($0.400) | 17% |
|
| Operating Cash Flow (TTM) (Mil) | ($56) | ($3) | 9% |
|
| Net Cash Flow (TTM) (Mil) | $9 | $1 | 56% |
|
| Long-Term Debt (Q1) (Mil) | $5 | $25 | 24% |
|
| Enterprise Value (Q1) (Mil) | $978 | $399 | 40% |
|
| Valuation | BBNX | Industry Median |
Percentile (All Stocks) |
|
| P/B | 3.31 | 2.74 | 70% |
|
| P/E | na | 24.9 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 1.4 | na |
|
| Ratios | BBNX | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 58.3% | 59.0% | 71% |
|
| Net Margin | (61.3%) | (6.9%) | 10% |
|
| ROA | (23.5%) | (12.3%) | 19% |
|
| ROE | (26.2%) | (10.8%) | 21% |
|
| Liabilities to Assets | 12.3% | 47.1% | 7% |
|
| F-Score | 2 | 4 | 7% |
|
Beta Bionics, Inc. did not pass any screens on 10/1/2026.
